Olema Pharmaceuticals (OLMA): Price and Financial Metrics

Olema Pharmaceuticals (OLMA): $4.71

-0.03 (-0.63%)

POWR Rating

Component Grades













Add OLMA to Watchlist
Sign Up

Industry: Biotech



in industry

OLMA Stock Price Chart Interactive Chart >

Price chart for OLMA

OLMA Price/Volume Stats

Current price $4.71 52-week high $7.41
Prev. close $4.74 52-week low $2.00
Day low $4.46 Volume 106,400
Day high $4.99 Avg. volume 221,722
50-day MA $3.11 Dividend yield N/A
200-day MA $3.48 Market Cap 190.54M

Olema Pharmaceuticals (OLMA) Company Bio

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

OLMA Latest News Stream

Event/Time News Detail
Loading, please wait...

OLMA Latest Social Stream

Loading social stream, please wait...

View Full OLMA Social Stream

Latest OLMA News From Around the Web

Below are the latest news stories about OLEMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OLMA as an investment opportunity.

Olema Pharmaceuticals Inc. (OLMA) is an excellent investment, but the stock is overvalued/undervalued right now

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) marked $4.01 per share on Thursday, up from a previous closing price of $3.92. While Olema Pharmaceuticals Inc. has overperformed by 2.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OLMA fell by -45.29%, with highs and lows ranging from $7.41 to […]

US Post News | January 13, 2023

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to three new employees to purchase an aggregate of 54,400 shares of the Company's common stock, effective as of January 3, 2023. These awards were approved by the Compensation

Yahoo | January 4, 2023

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET).

GlobeNewswire | January 3, 2023

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | January 2, 2023

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) Reduces -4.51% In A Week: What’s Lifting The Stock?

In last trading session, Olema Pharmaceuticals Inc. (NASDAQ:OLMA) saw 0.4 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.33 trading at -$0.12 or -4.90% at ring of the bell on the day assigns it a market valuation of $95.79M. That closing price of OLMA’s stock is … Olema Pharmaceuticals Inc. (NASDAQ:OLMA) Reduces -4.51% In A Week: What’s Lifting The Stock? Read More »

Marketing Sentinel | December 17, 2022

Read More 'OLMA' Stories Here

OLMA Price Returns

1-mo 89.92%
3-mo 26.95%
6-mo -4.85%
1-year -19.90%
3-year N/A
5-year N/A
YTD 92.24%
2022 -73.82%
2021 -80.53%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6481 seconds.